Key clinical point: Ixekizumab significantly improved the signs and symptoms of nonradiographic axial spondyloarthritis versus placebo.
Major finding: A 40% improvement in Assessment of Spondyloarthritis International Society response criteria was reached at week 16 by 19% of placebo patients and by 35% and 40% of the 2- and 4-week ixekizumab-group patients, and at week 52 by 13%, 30%, and 31% of the patients in the groups, respectively.
Study details: The randomized, placebo-controlled, phase 3 COAST-X trial of 303 patients.
Disclosures: COAST-X was sponsored by Eli Lilly. Dr. Deodhar and most coauthors reported receiving research grants and/or honoraria for consulting or speaking from Eli Lilly and other pharmaceutical companies. Four authors are current employees and shareholders of Eli Lilly.
Deodhar A et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract 2729.